Patent · US Expired

Peptide derivatives

US4775743A · kind A · utility

4Cited by
0References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 10, 1986
Grant dateOct 4, 1988
Priority date
Expiry dateSep 10, 2006

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

New peptide derivatives represented by the following general formula EQU R.sub.1 -Pro-Hyp-R.sub.2 wherein R.sub.1 is a hydrophobic radical, R.sub.2 is a hydrophilic radical, Pro is prolyl and Hyp is hydroxyprolyl show more powerful inhibitory action against platelet agglutination than conventional drugs and have potential use as anti-agglutination agent. The peptide derivative can be prepared by condensing a peptide containing a hydrophobic radical with a carboxylic acid containing a hydrophilic radical. The peptide derivative can be used in the form of parenteral injections, tablets, capsules or powder, the typical daily dose being in the range from 1 mg to 500 mg for adults.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.